INS and type 2 diabetes mellitus: Advances in nanotechnology, molecular and biomedical imaging tools, and drug delivery systems are offering new opportunities for early diagnosis and monitoring disease progression in patients with type 1 or type 2 diabetes combined with diminished insulin secretion [562].